Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KVD900 for on-demand treatment of hereditary angioedema attacks
2018-004489-32Phase 2Unknown
- Sponsor
- KalVista Pharmaceuticals
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sebetralstat in hereditary angioedema (HAE) (2 arms), sponsored by KalVista Pharmaceuticals. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Status: unknown.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2018-004489-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004489-32.